Clinicopathologic Correlations in Histopathologic Report of Placenta: Can We Do Something More?

Giacometti, Cinzia; Cassaro, Mauro

doi:10.5858/arpa.2016-0414-le

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Discussion with placental pathologists and obstetricians is essential for interpreting how the timing and presence of multiple lesions and their potential synergistic effects could have contributed to certain neonatal clinical presentations. These criteria and patterns have been leveraged over the years by various groups ( 5 , 6 ) and provide significant data that the neonatologist can use to understand the intrauterine environment and exposures during fetal development, with implications for management of critically ill neonates.…”

Section: Gross and Histologic Features Of The Placenta: Relevance To ...mentioning

confidence: 99%

Leveraging the placenta to advance neonatal care

Mestan,

Leibel,

Sajti

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

The impact of placental dysfunction and placental injury on the fetus and newborn infant has become a topic of growing interest in neonatal disease research. However, the use of placental pathology in directing or influencing neonatal clinical management continues to be limited for a wide range of reasons, some of which are historical and thus easily overcome today. In this review, we summarize the most recent literature linking placental function to neonatal outcomes, focusing on clinical placental pathology findings and the most common neonatal diagnoses that have been associated with placental dysfunction. We discuss how recent technological advances in neonatal and perinatal medicine may allow us to make a paradigm shift, in which valuable information provided by the placenta could be used to guide neonatal management more effectively, and to ultimately enhance neonatal care in order to improve our patient outcomes. We propose new avenues of clinical management in which the placenta could serve as a diagnostic tool toward more personalized neonatal intensive care unit management.

show abstract

Section: Gross and Histologic Features Of The Placenta: Relevance To ...mentioning

confidence: 99%

Leveraging the placenta to advance neonatal care

Mestan,

Leibel,

Sajti

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…This phenomenon is associated with a lower capacity of adenosine transport via human equilibrative nucleoside transporters (hENTs) by HUVEC and hPMEC in GDM [ 12 ]. The histological hallmark of the effects of GDM on placental maturation is the so-called delay of villous maturation (DVM), which also encompasses the decreased formation of vasculo-syncytial membranes, the presence of multiple centrally located capillaries and a variable extent of chorangiosis [ 13 , 14 ]. Placental villous maturation reaches the highest point in the 3rd trimester, with an abundance of terminal villi, defined by small-caliber vessels (40–100 µm), minimal stroma, and abundant vasculo-syncytial membrane (VSM) formation [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?

Giacometti¹,

Ludwig

Guidi

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a metabolic disease that can affect placental villous maturation and villous vascularity. The main effects of GDM on placental growth are a delay of villous maturation (DVM) and decreased formation of vasculo-syncytial membranes (VSM). Human equilibrative nucleoside transporter-1 (hENT1) is an adenosine transporter expressed in the human umbilical vein endothelial cells (HUVEC) and human placental microvascular endothelium cells (hPMEC). Its role is crucial in maintaining physiological fetal adenosine levels during pregnancy, and its reduction has been described in GDM. Twenty-four placentas from pregnancies with a confirmed diagnosis of GDMd and twenty-four matched non-GDM placentas (controls) were retrospectively analyzed to investigate the immunohistochemical expression of hENT1 in HUVEC and hPMEC. The study included the quantitative evaluation of VSM/mm2 in placental tissue and the immunohistochemical quantitative evaluation of Ki-67, PHH3, and p57 in villous trophoblast. hENT1 expression was higher in all the vascular districts of the control cases compared to the GDMd placentas (p < 0.0001). The VSM/mm2 were lower in the GDMd cases, while the Ki-67, PHH3, and p57 were higher when compared to the control cases. To our knowledge, this is the first report of hENT1 expression in the human placentas of GDM patients. The absence/low expression of hENT1 in all the GDMd patients may indicate a potential role in microvascular adaptative mechanisms. The trophoblasts’ proliferative/antiapoptotic pattern (high Ki-67, high PHH3, and high p57 count) may explain the statistically significant lower number of VSM/mm2 found in the GDMd cases.

show abstract

Clinicopathologic Correlations in Histopathologic Report of Placenta: Can We Do Something More?

Cited by 2 publications

References 5 publications

Leveraging the placenta to advance neonatal care

Leveraging the placenta to advance neonatal care

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?

Contact Info

Product

Resources

About